Document Detail


Adalimumab for psoriasis in Greece: clinical experience in a tertiary referral centre.
MedLine Citation:
PMID:  21967627     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Adalimumab, a fully human, anti-TNFα monoclonal antibody has been shown to be effective for moderate-to-severe psoriasis in clinical trial setting. However, only a limited number of studies reflect everyday clinical experience with this drug.
OBJECTIVES: To provide evidence on the efficacy, dose optimization and safety of adalimumab based on everyday clinical experience in a tertiary referral centre for psoriasis, in Greece.
METHODS: We retrospectively reviewed the records of all patients with moderate-to-severe psoriasis who received adalimumab, in our referral centre, between January 2008 and October 2010.
RESULTS: In total, 52 patients were treated with adalimumab for a mean period of 14 months (range 4-30 months). Mean baseline Psoriasis Area and Severity Index (PASI) was 16.7 (range 9-40.3). At 4, 6, 12 and 18 months, PASI75 was attained by 68%, 82%, 89% and 88% of patients respectively. Nineteen of 52 patients (36%) reached a PASI100 at a mean time of 10 months (range 4-18 months). The dose interval between the injections of adalimumab was increased from 2 to 3 weeks for 14 patients (27%) who achieved and sustained a PASI100 after the first year of treatment, without any relapse. The overall rate of adverse events reached 38%, but treatment was discontinued only in two cases (4%).
CONCLUSIONS: Our study demonstrates that adalimumab is effective and safe in patients with moderate-to-severe psoriasis in short- and long-term setting. At the same time, it points out novel and interesting issues for further investigation.
Authors:
C Fotiadou; E Lazaridou; E Sotiriou; D Ioannides
Related Documents :
25410147 - 12 month experience with the gore® tigris® vascular stent in the superficial femoral ...
21747007 - Repeated treatment with rituximab based on the assessment of peripheral circulating mem...
21615437 - Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therap...
10977467 - Proton pump inhibitor therapy: preliminary results of a therapeutic interchange program.
21264137 - Normobaric oxygen therapy in acute ischemic stroke: a pilot study in indian patients.
20417447 - Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprote...
Publication Detail:
Type:  Journal Article     Date:  2011-10-04
Journal Detail:
Title:  Journal of the European Academy of Dermatology and Venereology : JEADV     Volume:  26     ISSN:  1468-3083     ISO Abbreviation:  J Eur Acad Dermatol Venereol     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-09-10     Completed Date:  2013-01-15     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  9216037     Medline TA:  J Eur Acad Dermatol Venereol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1298-303     Citation Subset:  IM    
Copyright Information:
© 2011 The Authors. Journal of the European Academy of Dermatology and Venereology © 2011 European Academy of Dermatology and Venereology.
Affiliation:
First Department of Dermatology-Venereology, Aristotle University Medical School, Thessaloniki, Greece. cifotiadou@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Anti-Inflammatory Agents / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Female
Greece
Humans
Male
Middle Aged
Psoriasis / drug therapy*
Retrospective Studies
Tertiary Healthcare*
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Antibodies, Monoclonal, Humanized; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Non-invasive detection of concealed explosives: Depth profiling through opaque plastics by Time-Reso...
Next Document:  Glucocorticoid and polyamine interactions in the plasticity of glutamatergic synapses that contribut...